An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

Key Takeaways An experimental drug can delay disability progression in advanced multiple sclerosis patientsTolebrutinib ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

A poll conducted in April and May of 2024 found that around 12 percent of Americans have tried a GLP-1 drug such as Ozempic, Wegovy, Zepbound, or Mounjaro—a number that has likely only grown ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can "silence" the main gene responsible for ...

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England ...

WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder ...